[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,011,896
  • Shares Outstanding, K 52,566
  • Annual Sales, $ 60 K
  • Annual Income, $ -78,260 K
  • EBIT $ -73 M
  • EBITDA $ -73 M
  • 60-Month Beta 0.78
  • Price/Sales 17,783.35
  • Price/Cash Flow N/A
  • Price/Book 7.80

Options Overview Details

View History
  • Implied Volatility 80.51% (+2.62%)
  • Historical Volatility 82.00%
  • IV Percentile 6%
  • IV Rank 7.07%
  • IV High 506.06% on 05/04/26
  • IV Low 48.13% on 09/04/25
  • Expected Move (DTE 8) 0.00 (0.00%)
  • Put/Call Vol Ratio 2.00
  • Today's Volume 30
  • Volume Avg (30-Day) 208
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 11,123
  • Open Int (30-Day) 27,063
  • Expected Range 19.21 to 19.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.66
  • Number of Estimates 6
  • High Estimate $-0.52
  • Low Estimate $-0.94
  • Prior Year $-1.92
  • Growth Rate Est. (year over year) +65.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.52 +53.43%
on 06/09/26
20.65 -6.97%
on 07/07/26
+6.47 (+50.78%)
since 06/08/26
3-Month
12.51 +53.56%
on 04/29/26
24.27 -20.85%
on 05/07/26
+4.80 (+33.31%)
since 04/08/26
52-Week
4.61 +316.70%
on 07/11/25
24.27 -20.85%
on 05/07/26
+14.36 (+296.08%)
since 07/08/25

Most Recent Stories

More News
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Appoints Ron Philip to Board of Directors

WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

IND submission for AVTX-010 planned for the first half of 2027 WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 program Completed public...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It

Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It

Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It

Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Announces Pricing of $375 Million Public Offering

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated...

AVTX : 19.21 (-0.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is...

See More

Key Turning Points

3rd Resistance Point 21.39
2nd Resistance Point 20.62
1st Resistance Point 19.91
Last Price 19.21
1st Support Level 18.43
2nd Support Level 17.66
3rd Support Level 16.95

See More

52-Week High 24.27
Last Price 19.21
Fibonacci 61.8% 16.76
Fibonacci 50% 14.44
Fibonacci 38.2% 12.12
52-Week Low 4.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.